1 May 2026Open access
Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trialPublisher siteOpen Forum Infectious Diseases, HIV/AIDS drug development and treatment
UniversitiesEbrahim Variava
Active, last published 2026
In respiratory viral infections research
Ebrahim
Variava
Scholar“Research focused on Respiratory viral infections research and adjacent fields.”
University of the Witwatersrand
Claim Your Profile39
H-index
5.8k
Citations
Ebrahim has not officially claimed their profile. If you are Ebrahim, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
brahim Variava is a researcher working on Respiratory viral infections research. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Ebrahim's work has been cited 5,843 times across 2 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Respiratory viral infections research×55Tuberculosis Research and Epidemiology×49Pneumonia and Respiratory Infections×48Pneumocystis jirovecii pneumonia detection and treatment×40HIV/AIDS Research and Interventions×36
04 · Where I am
Affiliations
Affiliation on published researchUniversity of the WitwatersrandDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
16 works9 Apr 2026Open access
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trialPublisher siteClinical Infectious Diseases, HIV-related health complications and treatments
24 Mar 2026Open access
Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trialPublisher siteTrials, Fungal Infections and Studies
19 Mar 2026Open access
The use of multiplex PCR for the detection of respiratory pathogens in hospitalised adults with community-acquired pneumonia during the pre-COVID era in South Africa: A retrospective cohortPublisher siteResearch Square, Pneumonia and Respiratory Infections
17 Mar 2026Open access
SAHCS Guideline for the prevention, diagnosis and management of cryptococcal disease among persons living with HIV: Update to induction treatment for cryptococcal meningitisPublisher siteSouthern African Journal of HIV Medicine, Fungal Infections and Studies
20 Dec 2024Open access
Steatotic liver disease in people with HIV at Tshepong Hospital: A post-mortem analysisPublisher siteSouthern African Journal of HIV Medicine, Liver Disease Diagnosis and Treatment
1 Dec 2024Open access2cites
Cohort profile: the potentially preventable burden of community-acquired pneumonia in South African adults in the era of widespread PCV13 immunisation and antiretroviral therapy roll-out, before and during the COVID-19 pandemic – the multicentre, multimethod PotPrev StudyPublisher siteBMJ Open, Pneumonia and Respiratory Infections
30 Oct 2024Open access1cites
Hypertension guideline implementation and blood pressure control in Matlosana, South AfricaPublisher siteSouth African Family Practice, Health Sciences Research and Education
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Ebrahim?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you